Evaluation of efficacy of I125Brachytherapy combined with low-dose radiotherapy and hormontherapy in Treating intermediate and advanced prostate cancer
Department of Urology, Xuzhou Cancer Hospital, Xuzhou 221005,China
Objective: To investigate the clinical outcome and side effects of low-dose I125Brachytherapy(BT)combined with intensity modulated radiotherapy(IMRT) and Intermittent AndrogenDeprivation(IHT)for the treatment of advanced prostate cancer. Methods:The clinical data of 16cases of prostate carcinoma treated with tri-modality were retrospectively analyzed.All the T3and T4 stage patients received Brachytherapy and IMRT. 25cases in the control group only received intermittent AndrogenDeprivation.Results:The mean fo1low-up duration was 46 months(21-62months).Compared with the control group, PSA、 IPSS score and prostate volume, urinary flow rate decreased significantly (P <0.05).The5-year overall survival rates were 48.3% and43.2% respectively (p<0.05).Conclusions: Tri-modality therapy can increase the local
toxicity of the surroundingdosage of radiation and decrease the biochemical recurrence in prostate cancer．The rate of tissues is low and patients can gain good tolerability and have quality life．
曹敬毅，王淇超，王 乾，吴 刚. I125放射性粒子植入联合低剂量调强适行放疗及内分泌治疗在中晚期前列腺癌中的临床疗效评价[J]. 国际泌尿系统杂志, 2015, 35(3): 324-327.
Cao Jingyi, Wang Qichao, Wang Qian, Wu Gang. Evaluation of efficacy of I125Brachytherapy combined with low-dose radiotherapy and hormontherapy in Treating intermediate and advanced prostate cancer. journal1, 2015, 35(3): 324-327.
